''For Dr. Tran's success last spring at Providence Hospital in Oregon, an autologous, viral-vectored targeting of a patient with a single neoantigen is a challenge.''

No, two patients were treated, one with two TCRs targeting the same the HLA-restricted shared neoantigen. Focusing on the first, they showed signs of short-term tumour regression, with shrinking or stable lesions, reduced pain, and reduced tumour markers. Despite additional treatment with an anti-PD-1 and chemo, progressed and died of disease. As for the second, they experienced a 72% partial response at six months. However, after about a year, showed slow progression of a lung lesion, which was resected and is currently under investigation. This patient was also recently re-treated with TCR-T cells (this time with only one of the TCRs) plus an anti-PD-1.

''Neogene/AZN utilizes the DNA cutter, CRSPR/Cas9. While I expect that one day research will provide the solution, I have yet to come across a published paper that asserts that the concern of "random, unintended cuts of the human genome" by CRSPR/Cas9 has been resolved.''

Try looking at Neogene's own data https://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-TP53-R175H-TCR-poster-final-edit.pdf